Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma;…
| Periodo | 2026-11 | 2022-04 | 2021-04 | 2020-09 |
|---|---|---|---|---|
| Real | — | $-0.15 | $0.10 | $0.06 |
| Estimado | — | $-0.12 | $0.07 | $0.22 |
| Sorpresa | — | -25.0% | +42.9% | -72.7% |
| Métrica | IPH.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -256.3% | -34.4% | -221.9% |
| Net Margin | -245.9% | -32.5% | -213.4% |
| FCF Margin | -36.2% | -12.6% | -23.6% |
| ROE | -560.0% | -39.2% | -520.8% |
| ROA | -44.5% | -30.9% | -13.6% |
| Current Ratio | 2.60 | 2.73 | -0.13 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -44.5% | — |
| ✗Flujo de caja operativo positivo | −€7M | −€33M |
| ✗Rentabilidad sobre activos al alza | -44.5% | -4.3% |
| ✓Caja operativa/activos supera al ROA | -6.2% | ROA -44.5% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 2.60 | 3.73 |
| ✗Sin aumentar el nº de acciones | 81M | 80M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.18 | 0.35 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -36.2% |
| ✗ROCE > 10 % | -66.1% |
| ✗Ventas > 5 %/año (3 años) | -6.6% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 260.3% |
INNATE PHARMA cotiza a 1.30 EUR y tiene una capitalización bursátil de €145M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud